⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Salubris Biotherapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Salubris Biotherapeutics, Inc.
↗Gaithersburg, Maryland, USA
Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody and protein-based therapeutics. The company specializes in creating complex biologics to address significant unmet medical needs in cardiovascular, oncology, and neurodegenerative diseases.
Founded in 2016, SalubrisBio operates as a wholly-owned subsidiary of the China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co. Ltd. Headquartered in Gaithersburg, Maryland, the company leverages its U.S.-based R&D capabilities to drive innovation and global market expansion for its parent organization.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Cardiovascular Therapeutics
SIZE & FINANCIALS
Employees:1-50
Founded:2016
Ownership:subsidiary
Status:operating
FUNDING
Stage:Private
Total Raised:$35M (latest disclosed round)
Investors:Shenzhen Salubris Pharmaceuticals Co. Ltd.
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Antibody fusion proteins, Antibody-drug conjugates (ADC), Biologics
Active Trials:6
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Shenzhen Salubris Pharmaceuticals Co. Ltd.
Key Partnerships:MabPlex (CMC and ADC development partner)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Sam Murphy - CEO
Shalabh Singhal - Chief Medical Officer
Jijun Dong - Chief Scientific Officer
LINKS
Website:salubrisbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Salubris Biotherapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.